Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION RWE protocol that may not meet regulator expectations arrived with a competitor label that just got a narrower indication. CMC change-control owner in a safety team sitting on a new disproportionate signal still has an evidence gap on whether to drop a secondary endpoint that will dominate the AdCom.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. RWE protocol that may not meet regulator expectations reads as Proceed under protocol once a competitor label that just got a narrower indication is lined up to the same Pharma & Life Sciences population. 2. RWE protocol that may not meet regulator expectations is closer to Pause the pathway after a competitor label that just got a narrower indication; Proceed under protocol would over-claim this Clinical and Evidence Strategy extract. 3. Escalate safety review is still live in RWE protocol that may not meet regulator expectations for CMC change-control owner in a safety team sitting on a new disproportionate signal. 4. RWE protocol that may not meet regulator expectations is missing the fact CMC change-control owner needs after a competitor label that just got a narrower indication; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim CMC change-control owner would keep. 3. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against a competitor label that just got a narrower indication and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in RWE protocol that may not meet regulator expectations, then the action for CMC change-control owner - Hypothesis scorecard against RWE protocol that may not meet regulator expectations: supported / rejected / untestable - Clinical and Evidence Strategy finding in RWE protocol that may not meet regulator expectations that a second reviewer can re-perform - Missing page in RWE protocol that may not meet regulator expectations after a competitor label that just got a narrower indication, if any